Mode
Text Size
Log in / Sign up

Histopathology and methylome profiling confirm metastatic recurrence 13 years after curative treatment for GEJAA brain tumor appears 13 years after cancer treatment

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider histopathology and methylome profiling to confirm late metastatic recurrence in patients with prior malignancies.

This case report and review of the literature describes a 58-year-old patient with Siewert type II gastroesophageal junction adenocarcinoma (GEJA) who presented with a solitary brain metastasis 13 years after receiving curative-intent multimodality treatment. The diagnosis of the intracranial lesion was confirmed as a metastatic recurrence from the prior GEJA through a combination of histopathology, immunohistochemistry, and methylome profiling.

The authors emphasize that the case highlights the importance of tissue confirmation and integrated pathological assessment for intracranial lesions appearing many years after curative treatment. The findings suggest that late metastatic recurrence should be included in the differential diagnosis of symptomatic brain lesions in long-term cancer survivors.

A primary limitation of this evidence is the small sample size, as it is based on a single case report. The authors note that the case does not imply a role for routine neuroimaging in asymptomatic long-term survivors. The clinical relevance lies in the diagnostic workup of late-presenting neurological symptoms in patients with a history of malignancy.

How this fits prior evidence

This case report addresses a gap in the clinical understanding of late-presenting metastatic disease. While other evidence notes that NODI parameters ODI and V-ISO can help differentiate gliomas from brain metastases in contrast-enhancing regions, this case highlights the role of histopathology and methylome profiling in confirming recurrence years after treatment. It also contributes to the broader clinical context of managing brain metastases, which has been discussed in other reports regarding local therapies and microenvironment mechanisms.

Imagine finishing a long, difficult road of cancer treatment and feeling like you have finally won the fight. For one woman, that peace lasted for over a decade. She had been treated for a specific type of cancer at the junction of her esophagus and stomach. She lived well for 13 years before a new issue appeared in her brain.

Doctors used several tests, including tissue samples and genetic profiling, to look at the new growth. They confirmed that the brain tumor was actually a late return of her original cancer. This case shows that even when a patient is far past their treatment date, a previous cancer can still reappear in a different part of the body.

Because this was a single case, it does not mean everyone needs constant brain scans. However, it does remind doctors to look closely at any new brain issues in patients who had cancer years ago. It highlights how important it is to use detailed testing to figure out exactly what a new growth is.

What this means for you:
A patient's cancer returned in her brain 13 years after she finished treatment.

Common questions

Can cancer return many years after treatment?

Yes, this case shows a patient who developed a brain tumor 13 years after she received treatment for a specific type of esophageal cancer. While this is not common, it shows that a previous cancer can reappear in a different part of the body even a long time after the initial treatment is finished.

How did doctors confirm the brain tumor was from the old cancer?

Doctors used three specific methods to confirm the diagnosis: histopathology, immunohistochemistry, and methylome profiling. These tests allowed them to confirm that the brain growth was a recurrence of the patient's original cancer from over a decade earlier.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedOct 2026
View Original Abstract ↓
Brain metastases in gastroesophageal adenocarcinoma are uncommon and can cause substantial neurological morbidity. Here, we report the case of a 58-year-old patient who developed a solitary brain metastasis thirteen years after curative-intent multimodality treatment for a Siewert type II gastroesophageal junction adenocarcinoma (GEJA). The intracranial lesion was initially radiologically suspected to be a primary brain tumour, while systemic restaging showed no extracranial disease. Histopathology, immunohistochemistry, clinical history, and methylome profiling supported metastatic recurrence from the prior GEJA. This case is noteworthy for the exceptionally long disease-free interval, the brain-only presentation after routine oncological surveillance had ended, and the diagnostic importance of tissue confirmation and integrated pathological assessment when a new intracranial lesion appears many years after curative treatment. This case supports maintaining late metastatic recurrence in the differential diagnosis of symptomatic brain lesions without implying a role for routine neuroimaging in asymptomatic long-term survivors.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.